Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TScan TherapeuticsTCRX -3.15%44 PB Ratio is 0.72 as of Aug. 31, 2026, which is 11% above its 10-year median of 0.65. GuruFocus rates TCRX with a GF Score™ of 44/100 and a GF Value™ of $1.32 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,216 Biotechnology companies, TScan Therapeutics ranks better than 89.06% on this metric.
The historical rank and industry rank for TScan Therapeutics's PB Ratio or its related term are showing as below:
TCRX'
s PB Ratio Range Over the Past 10 Years
Min: 0.3 Med: 0.65 Max: 3.5
Current: 0.72
During the past 7 years, TScan Therapeutics's highest PB Ratio was 3.50. The lowest was 0.30. And the median was 0.65.
TCRX's PB Ratio is ranked better than 89.06% of 1216
companies
in the Biotechnology industry
Industry Median: 2.925
vs TCRX: 0.72
During the past 12 months, TScan Therapeutics's average Book Value Per Share Growth Rate was -67.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -19.20% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of TScan Therapeutics was -14.10% per year. The lowest was -19.20% per year. And the median was -16.65% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
TScan Therapeutics PB Ratio Related Terms
TScan Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for TScan Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, TScan Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TScan Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TScan Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where TScan Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
TScan Therapeutics (TCRX) has a PB Ratio of 0.72 as of Aug. 31, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on TScan Therapeutics and its competitors. This is 11% above median its historical median of 0.65. Over the past decade, TScan Therapeutics' PB Ratio has ranged from 0.30 to 3.50. According to the industry distribution chart, TScan Therapeutics ranks #133 out of 1216 companies in the Biotechnology industry, placing it in the top 10.9%.
Is TScan Therapeutics' PB Ratio too high?
TScan Therapeutics' current PB Ratio of 0.72 is 11% above median its 10-year median of 0.65. Over the past 10 years, this metric has ranged from a low of 0.30 to a high of 3.50. The Biotechnology industry median PB Ratio is 2.93. TScan Therapeutics' value of 0.72 is 75.4% below this industry median. Based on the distribution chart, TScan Therapeutics ranks #133 out of 1216 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, TScan Therapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TScan Therapeutics' PB Ratio compare to MCRB and HYPD?
According to the Biotechnology industry distribution chart, TScan Therapeutics ranks #133 out of 1216 companies for PB Ratio. This places TScan Therapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.93. TScan Therapeutics' value of 0.72 is 75.4% below this benchmark. Historically, TScan Therapeutics' own PB Ratio has ranged from 0.30 to 3.50 over the past decade. While the company's 10-year median is 0.65 vs. the industry median of 2.93, TScan Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,216 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TScan Therapeutics's current PB Ratio of 0.72 is 75.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on TScan Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TScan Therapeutics's current PB Ratio is 0.72, which is 11% above median its own 10-year median of 0.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TScan Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, TScan Therapeutics (TCRX) is currently considered Possible Value Trap. The stock's GF Value™ is $1.32, compared to a current price of $0.73 — trading 44.7% below its estimated fair value. The current PB Ratio is 0.72, which is 11% above median its 10-year median of 0.65 and 75.4% below the Biotechnology industry median of 2.93. TScan Therapeutics' overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For TScan Therapeutics (TCRX), the current PB Ratio is 0.72 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TScan Therapeutics (TCRX) Overvalued in 2026?
Based on GuruFocus' analysis, TScan Therapeutics stock appears to be undervalued.
The current stock price of $0.73 is trading 44.7% below its estimated GF Value™ of $1.32.
GuruFocus considers TScan Therapeutics to be Possible Value Trap.
Key valuation signals for TCRX:
PB Ratio: 0.72 (11% above median its 10-year median of 0.65)
GF Value™: $1.32 vs. price of $0.73 (44.7% below fair value)
Industry Position: 75.4% below the Biotechnology median (#133 of 1216)
No single metric tells the full story. See the TCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
44GF Score
Get the complete analysis for TCRX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TCRX has been successfully added to your 
